Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00667342 · OUTCOME

2-Year Overall Survival (OS) in Patients With Localized Resectable Disease Compared to OS99 Protocol.

A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma · Source last updated 2023-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
probability
Interval / dispersion
95% Confidence Interval
Time frame
After all patients have completed therapy, up to 2 years after last patient is enrolled

What was measured

The current protocol OS2008 (NCT00667342) was closed early due to slow accrual. Thus, with the limited number of patients, the comparison of EFS of OS2008 to that of OS99 (NCT00145639) participants was not done. The 2-year OS of OS2008 participants is reported here.

Analysis population: OS2008 Localized Resectable Disease group had 31 participants: 7 were expired and 24 still alive

Groups in this outcome

A: Localized Resectable Disease

OS2008 Stratum A participants had primary tumors potentially resectable by aggressive surgery, such as limb-salvage surgery or amputation, and no evidence of metastasis.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
A: Localized Resectable Disease31

Reported measurements

Source class 1
Values in probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
A: Localized Resectable Disease0.934Not reported0.8471.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.847
        upper Limit
        1.0
        value
        0.934
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    units
    Participants
description
The current protocol OS2008 (NCT00667342) was closed early due to slow accrual. Thus, with the limited number of patients, the comparison of EFS of OS2008 to that of OS99 (NCT00145639) participants was not done. The 2-year OS of OS2008 participants is reported here.
dispersion Type
95% Confidence Interval
groups
  1. description
    OS2008 Stratum A participants had primary tumors potentially resectable by aggressive surgery, such as limb-salvage surgery or amputation, and no evidence of metastasis.
    id
    OG000
    title
    A: Localized Resectable Disease
param Type
NUMBER
population Description
OS2008 Localized Resectable Disease group had 31 participants: 7 were expired and 24 still alive
reporting Status
POSTED
time Frame
After all patients have completed therapy, up to 2 years after last patient is enrolled
title
2-Year Overall Survival (OS) in Patients With Localized Resectable Disease Compared to OS99 Protocol.
type
SECONDARY
unit Of Measure
probability

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice